← FDA DRUG APPROVALS

FDA ANDA · ANDA219350

LASMIDITAN

Sponsor: QILU PHARMACEUTICAL CO., LTD.

APPLICATION
ANDA219350
TYPE
ANDA
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

LASMIDITANNone (Tentative Approval)
LASMIDITAN 100MG · TABLET
LASMIDITANNone (Tentative Approval)
LASMIDITAN 50MG · TABLET

Approval history

2024-12-20UNKNOWN · Original · standardLetterTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →